Clinical trials in chemoprevention of head and neck cancers

Reviews on Recent Clinical Trials

Volumn 7, Issue 3, 2012, Pages 249-254

  Feng, Lining ^a   Wang, Zhi ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Chemoprevention; Head and neck; Larynx; Oral; Pharynx; Retinoids; Squamous cell carcinoma

Indexed keywords

ALPHA TOCOPHEROL; BIOLOGICAL MARKER; CELECOXIB; CHINESE DRUG; CURCUMIN; CYCLOOXYGENASE 2; EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT; HISTONE DEACETYLASE 1; INTERFERON; ISOTRETINOIN; KETOROLAC; LUTEOLIN; LYCOPENE; PROSTAGLANDIN SYNTHASE INHIBITOR; RESVERATROL; RETINOID DERIVATIVE; RETINOL; SPHINGOSINE KINASE 1; UNCLASSIFIED DRUG; ZENGSHENGPING;

CANCER MORTALITY; CANCER PATIENT; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DISEASE FREE SURVIVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG PENETRATION; DRUG TOLERABILITY; FRUIT; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VEGETABLE;

ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; HEAD AND NECK NEOPLASMS; HUMANS;

EID: 84866680547     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/157488712802281349     Document Type: Review

References (61)

1. Kim JW, Amin AR, Shin DM, et al. Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prev Res (Phila) 2010; 3: 900-9.
2. Gao, X, Fisher SG, Mohideen N, et al. Second primary cancers in patients with laryngeal cancer: a population-based study. Int J Radiat Oncol Biol Phys 2003; 56: 427-35.
3. Gustin DM. Chemoprevention of head and neck cancer. Semin Oncol 2004; 31: 769-77.
4. Tamimi RM, Lagiou P, Adami HO, et al. Prospects for chemoprevention of cancer. J Intern Med 2002; 251: 286-300.
5. Rahman MA, Amin AR, Shin DM, et al. Chemopreventive potential of natural compounds in head and neck cancer. Nutr Cancer 2010; 62: 973-87.
6. Kakizoe T. Chemoprevention of cancer-focusing on clinical trials. Jpn J Clin Oncol 2003; 33: 421-42.
7. Tanaka T, Tanaka M. Oral carcinogenesis and oral cancer chemoprevention: a review. Pathol Res Int 2011: 431246.
8. Papadimitrakopoulou VA, Lee JJ, William WN, et al. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 2009; 27: 599-604.
9. Perry CF, Stevens M, Rabie I, et al. Chemoprevention of head and neck cancer with retinoids: a negative result. Arch Otolaryngol Head Neck Surg 2005; 131: 198-203.
10. Khuri FR, Kim ES, Lee JJ. et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2001; 10: 823-9.
11. Khuri FR, Lee JJ, Lippman SM, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 2006; 98: 441-50.
12. Toma S, Bonelli L, Sartoris A, et al. 13-cis retinoic acid in head and neck cancer chemoprevention: results of a randomized trial from the Italian Head and Neck Chemoprevention Study Group. Oncol Rep 2004; 11: 1297-305.
13. Bairati I, Meyer F, Gelinas M, et al. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol 2005; 23: 5805-13.
14. Bairati I, Meyer F, Gelinas M, et al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 2005; 97: 481-8.
15. Sanchez MJ, Martinez C, Nieto A, et al. Oral and oropharyngeal cancer in Spain: influence of dietary patterns. Eur J Cancer Prev 2003; 12: 49-56.
16. Smith W, Saba N. Retinoids as chemoprevention for head and neck cancer: where do we go from here? Crit Rev Oncol Hematol 2005; 55: 143-52.
17. Gorsky M, Epstein JB. The effect of retinoids on premalignant oral lesions: focus on topical therapy. Cancer 2002; 95: 1258-64.
18. Shin DM, Khuri FR, Murphy B, et al. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 2001; 19: 3010-7.
19. Seixas-Silva JA, Richards T, Khuri FR, et al. Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: longterm follow-up. Arch Otolaryngol Head Neck Surg 2005; 131: 304-7.
20. Mulshine JL, Atkinson JC, Greer RO, et al. Randomized, doubleblind, placebo-controlled phase II trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res 2004; 10: 1565-73.
21. Goodin S, Shiff SJ. NSAIDs for the chemoprevention of oral can cer: promise or pessimism?: Commentary re J. L. Mulshine et al., randomized, double-blind, placebo-controlled, phase IIB trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin. Cancer Res 2004; 10: 1565-73. Clin Cancer Res 2004; 10: 1561-4.
22. Cohen EG, Almahmeed T, Du B, et al. Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma. Clin Cancer Res 2003; 9: 3425-30.
23. Saba NF, Choi M, Muller S, et al. Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer Prev Res (Phila) 2009; 2: 823-9.
24. Banerjee AG, Gopalakrishnan VK, Bhattacharya I, et al. Deregulated cyclooxygenase-2 expression in oral premalignant tissues. Mol Cancer Ther 2002; 1: 1265-71.
25. Santhi WS, Sebastian P, Varghese BT, Prakash O, Pillai MR. NFkappaB and COX-2 during oral tumorigenesis and in assessment of minimal residual disease in surgical margins. Exp Mol Pathol 2006; 81: 123-30.
26. Papadimitrakopoulou VA, William WN, Dannenberg AJ, et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 2008; 14: 2095-101.
27. William WN, Lee JJ, Lippman SM, et al. High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila) 2009; 2: 22-6.
28. Boyle JO. Cyclooxygenase inhibition as a target for prevention of tobacco-related cancers. Clin Cancer Res 2004; 10: 1557-8.
29. Rajkumar T, Sridhar T, Balaram P, et al. Oral cancer in Southern India: the influence of body size, diet, infections and sexual practices. Eur J Cancer Prev 2003; 12: 135-43.
30. Steward DL, Wiener F, Gleich LL, et al. Dietary antioxidant intake in patients at risk for second primary cancer. Laryngoscope 2003; 113: 1487-93.
31. Chainani-Wu N. Diet and oral, pharyngeal, and esophageal cancer. Nutr Cancer 2002; 44: 104-26.
32. Davidson PG, Touger-Decker R. Chemopreventive role of fruits and vegetables in oropharyngeal cancer. Nutr Clin Pract 2009; 24: 250-60.
33. Llewellyn CD, Johnson NW, Warnakulasuriya KA, et al. Risk factors for oral cancer in newly diagnosed patients aged 45 years and younger: a case-control study in Southern England. J Oral Pathol Med 2004; 33: 525-32.
34. Petridou E, Zavras AI, Lefatzis D, et al. The role of diet and specific micronutrients in the etiology of oral carcinoma. Cancer 2002; 94: 2981-8.
35. Pavia MC, Pileggi C, Nobile CG, et al. Association between fruit and vegetable consumption and oral cancer: a meta-analysis of observational studies. Am J Clin Nutr 2006; 83: 1126-34.
36. Tavani A, Gallus S, La Vecchia C, et al. Diet and risk of oral and pharyngeal cancer. An Italian case-control study. Eur J Cancer Prev 2001; 10: 191-5.
37. Kushi LH, Byers T, Doyle C, et al. American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2006; 56: 254-81
38. Pisters KM, Newman RA, Coldman B, et al. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 2001; 19: 1830-8.
39. Tsao AS, Liu D, Martin J, et al. Phase II randomized, placebocontrolled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) 2009; 2: 931-41.
40. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res 2001; 21: 2895-900.
41. Sun Z, Guan X, Li N, et al. Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncol 2009; 46: 105-10.
42. Klass CM, Shin DM. Current status and future perspectives of chemoprevention in head and neck cancer. Curr Cancer Drug Targets 2007; 7: 623-32.
43. Jain S, Khuri FR, Shin DM, et al. Prevention of head and neck cancer: current status and future prospects. Curr Probl Cancer 2004; 28: 265-86.
44. Brown KS, Kane MA. Chemoprevention of squamous cell carcinoma of the oral cavity. Otolaryngol Clin North Am 2006; 39: 349-63.
45. Czerninski R, Amornphimoltham P, Patel V, et al. Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prev Res (Phila) 2009; 2: 27-36.
46. Lippman SM, Heymach JV. The convergent development of molecular-targeted drugs for cancer treatment and prevention. Clin Cancer Res 2007; 13: 4035-41.
47. Facchinetti MM, Gandini NA, Fermento ME, et al. The expression of sphingosine kinase-1 in head and neck carcinoma. Cells Tissues Organs 2010; 192: 314-24.
48. Shirai K, Kaneshiro T, Wada M, et al. A role of sphingosine kinase 1 in head and neck carcinogenesis. Cancer Prev Res (Phila) 2011; 4: 454-62.
49. Theocharis S, Klijanienko J, Giaginis C, et al. Histone deacetylase-1 and-2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. J Oral Pathol Med 2011; (Epub ahead of print).
50. Saintigny PL, Zhang L, Fan YH, et al. Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila) 2011; 4: 218-29.
51. Wang J, Lippman SM, Lee JJ, et al. Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. Carcinogenesis 2010; 31: 1755-61.
52. Zhang X, Yang H, Lee JJ, et al. MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. Carcinogenesis 2010; 31: 2118-23.
53. Lee JJ, Wu X, Hildebrandt MA, et al. Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) 2011; 4: 185-93.
54. Dawson MI. A strong case for personalized, targeted cancer prevention. Cancer Prev Res (Phila) 2011; 4: 173-6.
55. Pomerantz RG, Grandis JR. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. Semin Oncol 2004; 31: 734-43.
56. Choe MS, Zhang X, Shin H J, et al. Interaction between epidermal growth factor receptor-and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 2005; 4: 1448-55.
57. de Kok TM, van Breda SG, Manson MM, et al. Mechanisms of combined action of different chemopreventive dietary compounds: a review. Eur J Nutr 2008; 47 (Suppl 2): 51-9.
58. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010; 11: 781-89.
59. Rhee JC, Khuri FR, Shin DM, et al. Advances in chemoprevention of head and neck cancer. Oncologist 2004; 9: 302-11.
60. Wrangle JM, Khuri FR. Chemoprevention of squamous cell carcinoma of the head and neck. Curr Opin Oncol 2007; 19: 180-7.
61. Chow HH, Hakim IA. Pharmacokinetic and chemoprevention studies on tea in humans. Pharmacol Res 2011; 64: 105-12.